Rice Hall James & Associates LLC Purchases 7,643 Shares of Ingevity Corporation $NGVT

Rice Hall James & Associates LLC increased its position in Ingevity Corporation (NYSE:NGVT) by 2.3% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 345,138 shares of the company’s stock after acquiring an additional 7,643 shares during the quarter. Ingevity comprises 1.4% of Rice Hall James & Associates LLC’s investment portfolio, making the stock its 24th largest holding. Rice Hall James & Associates LLC owned approximately 0.99% of Ingevity worth $24,584,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the company. Principal Financial Group Inc. lifted its holdings in Ingevity by 269.9% during the fourth quarter. Principal Financial Group Inc. now owns 652,237 shares of the company’s stock valued at $38,599,000 after purchasing an additional 475,907 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Ingevity by 311.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 600,380 shares of the company’s stock worth $23,769,000 after purchasing an additional 454,579 shares in the last quarter. Simcoe Capital Management LLC increased its stake in shares of Ingevity by 188.8% in the second quarter. Simcoe Capital Management LLC now owns 624,935 shares of the company’s stock worth $26,928,000 after purchasing an additional 408,508 shares in the last quarter. Boston Partners raised its position in shares of Ingevity by 141.6% in the fourth quarter. Boston Partners now owns 620,360 shares of the company’s stock valued at $36,719,000 after purchasing an additional 363,584 shares during the period. Finally, Bessemer Group Inc. lifted its stake in shares of Ingevity by 465.9% during the 1st quarter. Bessemer Group Inc. now owns 314,739 shares of the company’s stock valued at $22,419,000 after buying an additional 259,124 shares in the last quarter. Hedge funds and other institutional investors own 91.59% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on NGVT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ingevity in a report on Friday, July 17th. Wall Street Zen raised shares of Ingevity from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 7th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $80.00.

Ingevity Stock Down 0.7%

Shares of NYSE NGVT opened at $73.28 on Friday. The company has a quick ratio of 0.92, a current ratio of 1.42 and a debt-to-equity ratio of 27.83. The company has a market cap of $2.55 billion, a P/E ratio of -20.64 and a beta of 1.16. Ingevity Corporation has a 52 week low of $39.74 and a 52 week high of $79.29. The business has a 50-day simple moving average of $71.08 and a two-hundred day simple moving average of $70.62.

Ingevity (NYSE:NGVT) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.31. Ingevity had a positive return on equity of 207.82% and a negative net margin of 10.55%.The firm had revenue of $258.00 million for the quarter, compared to analysts’ expectations of $254.73 million. During the same period in the prior year, the business posted $1.01 earnings per share. The company’s revenue was up 4.1% on a year-over-year basis. Ingevity has set its FY 2026 guidance at 4.700-5.200 EPS. Research analysts anticipate that Ingevity Corporation will post 5.05 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, SVP Terrance M. Dyer sold 496 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $68.49, for a total transaction of $33,971.04. Following the sale, the senior vice president owned 7,202 shares of the company’s stock, valued at approximately $493,264.98. This represents a 6.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.88% of the company’s stock.

About Ingevity

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.